People with cystic fibrosis are prone to infections because of the thick, sticky mucus that clogs their airways. We are funding research to help fight these infections.
Chronic inflammation in people with cystic fibrosis causes damage to lung tissue that can eventually lead to respiratory failure. Researchers are trying to discover ways to dampen the exaggerated immune response that causes chronic inflammation without affecting the body's natural defenses against infection.
People with cystic fibrosis have thick, sticky mucus that blocks passages in their lungs, making it difficult for them to breathe and predisposing them to infections. New drugs are under development that will help break up and hydrate mucus in the lungs to make it easier to clear.
People with cystic fibrosis can experience complications in the pancreas, liver, and intestines that can lead to malnutrition, constipation, liver disease, and other digestive issues — including abdominal pain and poor appetite. Learn about research underway to address digestive system issues in CF.
Cystic fibrosis-related diabetes (CFRD) is a unique type of diabetes that is common in people with CF. Learn about research underway to improve CFRD diagnosis and treatment.
People with cystic fibrosis and their family members know CF better than anyone, and Community Voice provides opportunities for you to actively impact research, care, and programs for the CF community.
Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.
Yesterday, President Donald J. Trump signed the Right to Try bill into law. The House approved the bill last week and the Senate passed it last summer.
The top priority in clinical research is protecting the safety of people who participate. Learn more about the numerous layers of review that help keep participants safe.
The Patient Registry is an invaluable tool for researchers conducting observational studies about people with CF in the U.S. About 50,000 individuals have been followed in the Registry since its inception in 1986; many of them have been included for over 20 years.